LLY · News · 20260806N
Product / Drug Pipeline Progress - retatrutide
ELI LILLY & Co · 2026-08-06 · Importance 44 · Surprise 60 · In source text
Lilly began offering limited expanded access to investigational retatrutide before potential U.S. FDA approval. Eligibility is restricted to adults with refractory obesity, at least two serious obesity-related complications, and no ability to enroll in a clinical trial. Retatrutide targets three metabolic hormones and produced average weight loss of 22.6% at the highest weekly dose in trials. Lilly plans to submit the drug for FDA approval in the first quarter of 2027, positioning it as a next-generation competitor to Wegovy and other existing obesity treatments.
Key facts
- Seeking Alpha and other articles state Eli Lilly plans to file for FDA approval for retatrutide in Q1 2027. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Seeking Alpha and other articles state Eli Lilly plans to file for FDA approval for retatrutide in Q1 2027. |